Belgium – Antineoplastic and immunomodulating agents – Leveren van Pomalidomide - capsule 1 mg; 2 mg; 3 mg; 4 mg vs European Partnership on Rare Diseases (ERDERA) (Phase 2)
Side-by-side comparison of two grants.
| Attribute | Belgium – Antineoplastic and immunomodulating agents – Leveren van Pomalidomide - capsule 1 mg; 2 mg; 3 mg; 4 mg | European Partnership on Rare Diseases (ERDERA) (Phase 2) |
|---|---|---|
| Type | Tender | Grant |
| Funding amount | — | $103.9M |
| Deadline | Closes 2026-09-07 | Closes 2026-09-15 |
| Region | BEL | EU |
| Sector | Health | Health |
| Funder | UZ Leuven | European Commission (HORIZON) |
| Who it's for | — | researchers |